Scinai Immunotherapeutics Ltd. American Depositary Shares

Scinai Immunotherapeutics will lead a roundtable discussion at the 7th Dermatology Drug Development Summit Europe in Amsterdam, exploring how oral peptide and small molecule therapies may complement, compete with, or displace injectable biologic therapies in immunology and dermatology. The discussion will address key challenges including pharmaco...

Scinai Immunotherapeutics (NASDAQ: SCNI) received a Nasdaq notification on March 12, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share, as its closing bid price fell below this threshold for 30 consecutive business days. The company has been given 180 calendar days (until September 8, 2026) to regain compli...

Scinai Immunotherapeutics published research validating PC111, a novel monoclonal antibody targeting pemphigus and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), demonstrating potential as a disease-modifying therapy with a unique non-immunosuppressive mechanism.

Scinai Immunotherapeutics has regained full compliance with Nasdaq's listing requirements after converting $29 million of debt into equity, leaving a debt balance of $273,000. This clears the path for the company to focus on its R&D programs and CDMO business unit.

JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced receipt ...